The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Benzodiazepines Market Research Report 2024
Synopsis
Non-benzodiazepines are a relatively new class of hypnotics
Global Non-Benzodiazepines market is projected to reach US$ 1436.9 million in 2029, increasing from US$ 650 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Benzodiazepines market research.
Key manufacturers engaged in the Non-Benzodiazepines industry include Pfizer, Teva Pharmaceuticals, Torrent Pharma, Accord Healthcare, Akorn, Apotex, Fresenius Kabi, Hikma and Mylan, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Non-Benzodiazepines were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Benzodiazepines market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Benzodiazepines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Teva Pharmaceuticals
Torrent Pharma
Accord Healthcare
Akorn
Apotex
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Chenxin Pharmaceutical
Huatai Chenguang Pharmaceutical
Segment by Type
Dexmedetomidine
Zolpidem
Eszopiclone
Zopiclone
other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-Benzodiazepines report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Non-benzodiazepines are a relatively new class of hypnotics
Global Non-Benzodiazepines market is projected to reach US$ 1436.9 million in 2029, increasing from US$ 650 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Benzodiazepines market research.
Key manufacturers engaged in the Non-Benzodiazepines industry include Pfizer, Teva Pharmaceuticals, Torrent Pharma, Accord Healthcare, Akorn, Apotex, Fresenius Kabi, Hikma and Mylan, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Non-Benzodiazepines were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Benzodiazepines market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Benzodiazepines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Teva Pharmaceuticals
Torrent Pharma
Accord Healthcare
Akorn
Apotex
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Chenxin Pharmaceutical
Huatai Chenguang Pharmaceutical
Segment by Type
Dexmedetomidine
Zolpidem
Eszopiclone
Zopiclone
other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-Benzodiazepines report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Non-Benzodiazepines Market Overview
1.1 Product Overview and Scope of Non-Benzodiazepines
1.2 Non-Benzodiazepines Segment by Type
1.2.1 Global Non-Benzodiazepines Market Value Comparison by Type (2023-2029)
1.2.2 Dexmedetomidine
1.2.3 Zolpidem
1.2.4 Eszopiclone
1.2.5 Zopiclone
1.2.6 other
1.3 Non-Benzodiazepines Segment by Application
1.3.1 Global Non-Benzodiazepines Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Non-Benzodiazepines Market Size Estimates and Forecasts
1.4.1 Global Non-Benzodiazepines Revenue 2018-2029
1.4.2 Global Non-Benzodiazepines Sales 2018-2029
1.4.3 Global Non-Benzodiazepines Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Non-Benzodiazepines Market Competition by Manufacturers
2.1 Global Non-Benzodiazepines Sales Market Share by Manufacturers (2018-2023)
2.2 Global Non-Benzodiazepines Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Non-Benzodiazepines Average Price by Manufacturers (2018-2023)
2.4 Global Non-Benzodiazepines Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Non-Benzodiazepines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-Benzodiazepines, Product Type & Application
2.7 Non-Benzodiazepines Market Competitive Situation and Trends
2.7.1 Non-Benzodiazepines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Non-Benzodiazepines Players Market Share by Revenue
2.7.3 Global Non-Benzodiazepines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-Benzodiazepines Retrospective Market Scenario by Region
3.1 Global Non-Benzodiazepines Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Non-Benzodiazepines Global Non-Benzodiazepines Sales by Region: 2018-2029
3.2.1 Global Non-Benzodiazepines Sales by Region: 2018-2023
3.2.2 Global Non-Benzodiazepines Sales by Region: 2024-2029
3.3 Global Non-Benzodiazepines Global Non-Benzodiazepines Revenue by Region: 2018-2029
3.3.1 Global Non-Benzodiazepines Revenue by Region: 2018-2023
3.3.2 Global Non-Benzodiazepines Revenue by Region: 2024-2029
3.4 North America Non-Benzodiazepines Market Facts & Figures by Country
3.4.1 North America Non-Benzodiazepines Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Non-Benzodiazepines Sales by Country (2018-2029)
3.4.3 North America Non-Benzodiazepines Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-Benzodiazepines Market Facts & Figures by Country
3.5.1 Europe Non-Benzodiazepines Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Non-Benzodiazepines Sales by Country (2018-2029)
3.5.3 Europe Non-Benzodiazepines Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-Benzodiazepines Market Facts & Figures by Country
3.6.1 Asia Pacific Non-Benzodiazepines Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Non-Benzodiazepines Sales by Country (2018-2029)
3.6.3 Asia Pacific Non-Benzodiazepines Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-Benzodiazepines Market Facts & Figures by Country
3.7.1 Latin America Non-Benzodiazepines Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Non-Benzodiazepines Sales by Country (2018-2029)
3.7.3 Latin America Non-Benzodiazepines Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Non-Benzodiazepines Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-Benzodiazepines Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Non-Benzodiazepines Sales by Country (2018-2029)
3.8.3 Middle East and Africa Non-Benzodiazepines Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-Benzodiazepines Sales by Type (2018-2029)
4.1.1 Global Non-Benzodiazepines Sales by Type (2018-2023)
4.1.2 Global Non-Benzodiazepines Sales by Type (2024-2029)
4.1.3 Global Non-Benzodiazepines Sales Market Share by Type (2018-2029)
4.2 Global Non-Benzodiazepines Revenue by Type (2018-2029)
4.2.1 Global Non-Benzodiazepines Revenue by Type (2018-2023)
4.2.2 Global Non-Benzodiazepines Revenue by Type (2024-2029)
4.2.3 Global Non-Benzodiazepines Revenue Market Share by Type (2018-2029)
4.3 Global Non-Benzodiazepines Price by Type (2018-2029)
5 Segment by Application
5.1 Global Non-Benzodiazepines Sales by Application (2018-2029)
5.1.1 Global Non-Benzodiazepines Sales by Application (2018-2023)
5.1.2 Global Non-Benzodiazepines Sales by Application (2024-2029)
5.1.3 Global Non-Benzodiazepines Sales Market Share by Application (2018-2029)
5.2 Global Non-Benzodiazepines Revenue by Application (2018-2029)
5.2.1 Global Non-Benzodiazepines Revenue by Application (2018-2023)
5.2.2 Global Non-Benzodiazepines Revenue by Application (2024-2029)
5.2.3 Global Non-Benzodiazepines Revenue Market Share by Application (2018-2029)
5.3 Global Non-Benzodiazepines Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Non-Benzodiazepines Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Teva Pharmaceuticals
6.2.1 Teva Pharmaceuticals Corporation Information
6.2.2 Teva Pharmaceuticals Description and Business Overview
6.2.3 Teva Pharmaceuticals Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Pharmaceuticals Non-Benzodiazepines Product Portfolio
6.2.5 Teva Pharmaceuticals Recent Developments/Updates
6.3 Torrent Pharma
6.3.1 Torrent Pharma Corporation Information
6.3.2 Torrent Pharma Description and Business Overview
6.3.3 Torrent Pharma Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Torrent Pharma Non-Benzodiazepines Product Portfolio
6.3.5 Torrent Pharma Recent Developments/Updates
6.4 Accord Healthcare
6.4.1 Accord Healthcare Corporation Information
6.4.2 Accord Healthcare Description and Business Overview
6.4.3 Accord Healthcare Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Accord Healthcare Non-Benzodiazepines Product Portfolio
6.4.5 Accord Healthcare Recent Developments/Updates
6.5 Akorn
6.5.1 Akorn Corporation Information
6.5.2 Akorn Description and Business Overview
6.5.3 Akorn Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Akorn Non-Benzodiazepines Product Portfolio
6.5.5 Akorn Recent Developments/Updates
6.6 Apotex
6.6.1 Apotex Corporation Information
6.6.2 Apotex Description and Business Overview
6.6.3 Apotex Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Apotex Non-Benzodiazepines Product Portfolio
6.6.5 Apotex Recent Developments/Updates
6.7 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi Non-Benzodiazepines Product Portfolio
6.7.5 Fresenius Kabi Recent Developments/Updates
6.8 Hikma
6.8.1 Hikma Corporation Information
6.8.2 Hikma Description and Business Overview
6.8.3 Hikma Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikma Non-Benzodiazepines Product Portfolio
6.8.5 Hikma Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Mylan Non-Benzodiazepines Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Par Pharmaceuticals
6.10.1 Par Pharmaceuticals Corporation Information
6.10.2 Par Pharmaceuticals Description and Business Overview
6.10.3 Par Pharmaceuticals Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Par Pharmaceuticals Non-Benzodiazepines Product Portfolio
6.10.5 Par Pharmaceuticals Recent Developments/Updates
6.11 Sandoz
6.11.1 Sandoz Corporation Information
6.11.2 Sandoz Non-Benzodiazepines Description and Business Overview
6.11.3 Sandoz Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Sandoz Non-Benzodiazepines Product Portfolio
6.11.5 Sandoz Recent Developments/Updates
6.12 Sun Pharma
6.12.1 Sun Pharma Corporation Information
6.12.2 Sun Pharma Non-Benzodiazepines Description and Business Overview
6.12.3 Sun Pharma Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sun Pharma Non-Benzodiazepines Product Portfolio
6.12.5 Sun Pharma Recent Developments/Updates
6.13 WG Critical Care
6.13.1 WG Critical Care Corporation Information
6.13.2 WG Critical Care Non-Benzodiazepines Description and Business Overview
6.13.3 WG Critical Care Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.13.4 WG Critical Care Non-Benzodiazepines Product Portfolio
6.13.5 WG Critical Care Recent Developments/Updates
6.14 Athenex
6.14.1 Athenex Corporation Information
6.14.2 Athenex Non-Benzodiazepines Description and Business Overview
6.14.3 Athenex Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Athenex Non-Benzodiazepines Product Portfolio
6.14.5 Athenex Recent Developments/Updates
6.15 Chenxin Pharmaceutical
6.15.1 Chenxin Pharmaceutical Corporation Information
6.15.2 Chenxin Pharmaceutical Non-Benzodiazepines Description and Business Overview
6.15.3 Chenxin Pharmaceutical Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Chenxin Pharmaceutical Non-Benzodiazepines Product Portfolio
6.15.5 Chenxin Pharmaceutical Recent Developments/Updates
6.16 Huatai Chenguang Pharmaceutical
6.16.1 Huatai Chenguang Pharmaceutical Corporation Information
6.16.2 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Description and Business Overview
6.16.3 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Product Portfolio
6.16.5 Huatai Chenguang Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-Benzodiazepines Industry Chain Analysis
7.2 Non-Benzodiazepines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-Benzodiazepines Production Mode & Process
7.4 Non-Benzodiazepines Sales and Marketing
7.4.1 Non-Benzodiazepines Sales Channels
7.4.2 Non-Benzodiazepines Distributors
7.5 Non-Benzodiazepines Customers
8 Non-Benzodiazepines Market Dynamics
8.1 Non-Benzodiazepines Industry Trends
8.2 Non-Benzodiazepines Market Drivers
8.3 Non-Benzodiazepines Market Challenges
8.4 Non-Benzodiazepines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
